Cobra enters into manufacturing agreement to produce SARS protein in CHO cells

Published: 29-Feb-2008
Ingredients Sustainability Pharmaceutical

UK biopharma company Cobra Biomanufacturing has entered into a manufacturing development agreement with an undisclosed pharmaceutical company to produce a protein from the SARS virus in CHO (Chinese Hamster Ovary) cells under cGMP.


UK biopharma company Cobra Biomanufacturing has entered into a manufacturing development agreement with an undisclosed pharmaceutical company to produce a protein from the SARS virus in CHO (Chinese Hamster Ovary) cells under cGMP.

Cobra manufactures therapeutic proteins and vaccines for clinical trials, including Phase III and pre-market material, at its cGMP manufacturing facilities in Keele and Oxford, UK.

The pharmaceutical company will carry out the upstream manufacturing of the SARS protein and ship media containing the protein of interest to Cobra. Cobra will perform the downstream work to isolate and purify the protein. The SARS protein will be used in Phase I clinical trials.

"We are delighted to work with the company, which is one of the top global players on the biopharmaceutical market," said Simon Saxby, Cobra Biomanufacturing's chief operating officer. "This agreement will leverage Cobra's significant expertise in manufacturing recombinant proteins in compliance with worldwide cGMP requirements."

See more

You may also like

Manufacturing

Signal Group launches MCERTS approved VOC emissions monitor

Read more
New SOLAR CEMNEX analyser offers advanced compliance and connectivity features

Trending Articles

  1. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  2. Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target
  3. ProMach Pharma presents new equipment at Pack Expo Las Vegas Several new systems will be on exhibit for the first time, alongside other advanced processing and packaging equipment for pharmaceuticals, biopharmaceuticals, nutraceuticals, medical devices and more
  4. Bavarian Nordic launches chikungunya vaccine Vimkunya in the UK The UK announcement of the recombinant vaccine follows recent approval by the MHRA in May 2025
  5. FDA makes groundbreaking decision to waive clinical efficiency studies for monoclonal antibody biosimilars The University of Illinois secured the first-ever FDA acceptance to waive clinical efficiency studies (CESs) for the biological drugs

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Manufacturing

Signal Group launches MCERTS approved VOC emissions monitor

New SOLAR CEMNEX analyser offers advanced compliance and connectivity features
Packaging

ProMach Pharma presents new equipment at Pack Expo Las Vegas

Several new systems will be on exhibit for the first time, alongside other advanced processing and packaging equipment for pharmaceuticals, biopharmaceuticals, nutraceuticals, medical devices and more
Manufacturing

Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS

The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target
Pharmaceutical

CPHI Frankfurt 2025 to welcome more than 60,000 pharma professionals with expanded focus on innovation and sustainability

Returning to Germany from 28-30 October, CPHI Frankfurt 2025 will unite the global pharmaceutical supply chain with more than 2000 exhibitors, six content theatres and new feature zones
Manufacturing

Continuous innovation: redefining the future of pharmaceutical manufacturing

In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
Sustainability

Gerresheimer improves Rating Result and is once again awarded EcoVadis Gold

Gerresheimer, among the top 4% of all rated companies, whose rating reaches a new high with 78 out of 100 points, ranking among the top 1% of the industry underlines consistent implementation of the sustainability strategy
Pharmaceutical

Keystone Folding Box Co. unveils Key-Pak Plus

Designed to protect children and empower seniors, it achieves top U.S. safety ratings and meets global accessibility standards
Subscribe now